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Abstract
Aim: To assess the factors associated with antihyperglycaemic medication initiation in UK patients with newly
diagnosed type 2 diabetes.
Methods: In a retrospective cohort study, patients with newly diagnosed type 2 diabetes were identified during
the index period of 2003-2005. Eligible patients were ≥ 30 years old at the date of the first observed diabetes
diagnosis (referred to as index date) and had at least 2 years of follow-up medical history (N = 9,158). Initiation of
antihyperglycaemic medication (i.e., treatment) was assessed in the 2-year period following the index date.
Adjusted Cox regression models were used to examine the association between time to medication initiation and
patient age and other factors.
Results: Mean (SD) HbA1c at diagnosis was 8.1% (2.3). Overall, 51% of patients initiated antihyperglycaemic
medication within 2 years (65%, 55%, 46% and 40% for patients in the 30- < 45, 45- < 65, 65- < 75, 75+ age
groups, respectively). Among the treated patients, median (25
th,7 5
th percentile) time to treatment initiation was 63
(8, 257) days. Of the patients with HbA1c ≥ 7.5% at diagnosis, 87% initiated treatment within 2 years. These patients
with a higher HbA1c also had shorter time to treatment initiation (adjusted hazard ratio (HR) = 2.44 [95%
confidence interval (CI): 1.61, 3.70]; p < 0.0001). Increasing age (in years) was negatively associated with time to
treatment initiation (HR = 0.98 [95% CI: 0.97, 0.99]; p < 0.001). Factors significantly associated with shorter time to
treatment initiation included female gender and use of cardiovascular medications at baseline or initiated during
follow up.
Conclusions: In this UK cohort of patients with newly diagnosed type 2 diabetes, only 51% had
antihyperglycaemic medication initiated over a 2-year period following diagnosis. Older patients were significantly
less likely to have been prescribed antihyperglycaemic medications. Elevated HbA1c was the strongest factor
associated with initiating antihyperglycaemic medication in these patients.
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Background
Management of type 2 diabetes is centered on glycaemic
control, in conjunction with controlling blood pressure,
cholesterol, and other cardiovascular risk factors [1,2].
Diabetes treatment guidelines recommend initiating
treatment with antihyperglycaemic medication either
concomitantly with or following a brief period of life-
style intervention [1,3]. Despite these recommendations
and confirmed inadequate glycaemic control with life-
style interventions, many patients with newly diagnosed
type 2 diabetes remain untreated with antihyperglycae-
mic medication in clinical practice for extended periods
of time [4-7]. This hyperglycaemic burden may have
long-term consequences and increase the risk for both
micro- and macrovascular complications of diabetes [8].
Early initiation of antihyperglycaemic medication is
associated with reductions in microvascular events and
long-term, legacy effects with reductions in myocardial
infarction and death in patients with newly diagnosed
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antihyperglycaemic agents, as monotherapy, led to a 2-
to 3-fold increase in the proportion of patients with an
HbA1c < 7% relative to diet alone in patients with newly
diagnosed type 2 diabetes [12]. Initiation of antihyper-
glycaemic medication and treatment targets should be
based on clinical judgment following assessment of
patient factors such as age, functional status, and pre-
existing, co-morbid conditions and the risk of diabetes
treatment-related side effects (e.g., hypoglycaemia)
[1,3,8]. Given the increasing prevalence of type 2 dia-
betes in the UK [13], and the clinical benefits associated
with antihyperglycaemic treatments, the present study
was conducted to assess the association between patient
age and initiation of antihyperglycaemic medication in
UK patients following diagnosis of type 2 diabetes.
Methods
Data Source
The study cohort was drawn from the commercially-
available, widely-used Intercontinental Medical Statistics
(IMS) MediPlus database [14]. This database is com-
posed of patient information from a representative sam-
ple of general practitioners and contains records of
medical encounters, prescriptions, and enrollment data
for approximately 3.7 million patients in the UK and
Northern Ireland.
Study Design and Patient Selection
In this retrospective analysis, patients ≥ 30 years old
with newly diagnosed type 2 diabetes were identified
using International Classification of Disease (ICD)-10
codes (E11-E14) during the index period of 2003 to
2005. Newly diagnosed status was defined as having no
prior diagnosis of type 2 diabetes and no prescription
for antihyperglycaemic agents in the database for at
least 12 months prior to the first observed diagnosis (i.
e., index date). The age cut-off was chosen to minimise
the likelihood of selecting a patient with type 1 diabetes.
Patients included in this study were continuously active
in the database for at least 1 year preceding and 2 years
following the index date.
Analyses
The primary outcome was the proportion of patients
who initiated antihyperglycaemic medication (also
described as treatment or therapy for this analysis) dur-
ing the 2-year period following the index date. Time to
treatment initiation was calculated as the time between
the index date and first prescription for any antihyper-
glycaemic agent during the follow-up period. Data were
censored at 2 years of follow-up. The 2-year follow-up
period was selected to allow for sufficient time to initi-
ate medication following guideline treatment
recommendations, while also maximizing the size of the
cohort, since longer follow-up periods resulted in pro-
gressively smaller cohorts. Analyses were performed on
t h ee n t i r ec o h o r tw i t ha g ea sac o n t i n u o u sv a r i a b l ea n d
by age groups (30- < 45, 45- < 65, 65- < 75, and 75+
years).
Patient baseline characteristics were assessed using
data from the 12 months preceding the index date.
Characteristics included age at the index date, gender,
and co-morbid disease conditions. Limited laboratory
data are available in the MediPlus database. For the pre-
sent analysis, HbA1c values in the 6-month window cen-
tered on the index date (used as HbA1c at diagnosis [i.e.,
baseline] for analysis) were identified. This window was
selected to maximise the number a patients with HbA1c
values near the index date. Further, the potential 3-
month period beyond the index date was chosen
because the full effect of any diet or exercise interven-
tion was not likely attained within this short time per-
iod. HbA1c values were also identified during the 6-
month period prior to the end of the follow up (i.e., end
of study period) for all patients that were not treated
with antihyperglycaemic medications at the end of the
study period. The objective was to assess the association
between HbA1c values at the end of the study period
and non-treatment.
Descriptive statistics (mean and standard deviations
[ S D ]a n dp r o p o r t i o n s )w e r eu s e df o rp a t i e n td e m o -
graphics, co-morbid conditions, and treatment charac-
teristics. The Kaplan-Meier estimator of the survival
function was used to demonstrate differences in the
time to antihyperglycaemic treatment initiation across
different age groups. Cox regression models were used
to test for association between patient-related factors
and time to initiation of antihyperglycaemic treatment
adjusting for other predictors. Time-varying regression
variables were included in the models to account for
newly diagnosed conditions and newly prescribed (non-
antihyperglycaemic) medications during the follow-up
period. In the adjusted models, age was treated as a con-
tinuous variable and HbA1c at diagnosis was treated as a
categorical variable (< 7.5%, ≥ 7.5%, or missing). The
HbA1c cut point of 7.5% was selected because it is the
high point of the range recommended in the UK for
initiating antihyperglycaemic medication [15]. The chi-
square test was used to test for significance.
Results
In the MediPlus database, 43,486 patients had a diagno-
sis of type 2 diabetes. Of the 11,543 who had their first
observed diagnosis between 2003 and 2005, 9,158
patients (54% male) met the inclusion criteria for this
analysis. Mean (SD) age was 62.4 (12.8) years, with 9.6%,
44.3%, 27.5%, and 18.6% of patients within the 30- < 45,
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1). HbA1c values were available for 55% (n/N = 5,044/
9,158) of the entire cohort. There was no association
between age and missing HbA1c values (p = 0.3876 for
trend using chi-square test). Mean (SD) HbA1c at diag-
nosis was 8.1% (2.3) for the cohort of patients with
HbA1c values, and 8.7% (2.4), 8.3% (2.3), 8.0% (2.2), and
7.7% (2.0) for those in the 30- < 45, 45- < 65, 65- < 75,
75+ age groups, respectively. The presence of pre-exist-
ing co-morbid conditions at baseline increased with age,
except for liver disease where the opposite was observed
(Table 1). During the follow-up period, newly diagnosed
co-morbid conditions included cardiovascular conditions
(5.7%), microvascular complications of diabetes (7.2%),
cancer (1.8%), edema (1.7%), liver disease (0.5%), and
Alzheimer’s disease/dementia (0.2%). Use of antihyper-
tensive and gastroprotective agents increased with age,
whereas use of lipid-modifying agents was similar across
age groups (Table 1). Newly prescribed medications dur-
ing the follow-up included antihypertensive (10.1%),
lipid-modifying (28.6%), weight-reducing (1.6%), and
gastroprotective agents (6.3%).
Overall, 36%, 42%, and 51% of patients initiated anti-
hyperglycaemic therapy within 180 days, 1 year, and 2
years of diagnosis, respectively. The proportion of
patients who had treatment initiated within 2 years of
diagnosis decreased with advancing age (65%, 55%, 46%,
and 40% for patients in the 30- < 45, 45- < 65, 65- < 75,
75+ age groups, respectively). The median time to
treatment initiation increased with advancing age (213,
530, > 730, and > 730 days for patients in the 30- < 45,
45- < 65, 65- < 75, 75+ age groups, respectively [Figure
1]). Among the treated patients, median (25
th,7 5
th per-
centile) time to treatment initiation was 63 (8, 257)
days, with treatment initiation increasingly delayed with
age. Of the treatments prescribed, 76% of patients were
prescribed metformin, 19% sulphonylurea, 4% insulin,
and 1% other. Metformin use decreased with age (77%,
82%, 76%, and 66%, for patients in the 30- < 45, 45- <
65, 65- < 75, 75+ age groups, respectively; p < 0.0001
for trend using chi-square test) and sulphonylurea use
increased with age (15%, 15%, 22%, and 32%, respec-
tively; p < 0.0001 for trend using chi-square test).
Cox regression analysis adjusting for patients’ baseline
characteristics showed that increasing age was associated
with longer time to initiation of antihyperglycaemic
medication (Table 2). An HbA1c ≥ 7.5% at diagnosis was
associated with shorter time to treatment initiation
(Table 2). In this cohort of patients (i.e., HbA1c ≥ 7.5%
at diagnosis, n = 2,446), 73%, 81%, and 87% initiated
antihyperglycaemic therapy within 180 days, 1 year, and
2 years of diagnosis, respectively. There was a significant
interaction between age and HbA1c at diagnosis such
that the negative effect of age on treatment initiation
was reduced in individuals with higher HbA1c values at
diagnosis, i.e., ≥ 7.5% (Table 2). Other significant predic-
tors associated with shorter time to antihyperglycaemic
medication initiation included female gender, use of
Table 1 Baseline characteristics of patients with newly diagnosed type 2 diabetes during the index period
Variable Entire
Cohort
N = 9,158
Age Group (years)
30 to < 45
n = 880
45 to < 65
n = 4,055
65 to < 75
n = 2,522
≥ 75
n = 1,701
Age, years (mean ± SD) 62.4 ± 12.8 38.9 ± 4.0 55.8 ± 5.4 69.3 ± 2.8 80.1 ± 4.2
Gender, male (%) 54 54 60 55 41
HbA1c at diagnosis, % (mean ± SD) 8.1 ± 2.3 8.7 ± 2.4 8.3 ± 2.3 8.0 ± 2.2 7.7 ± 2.0
Patients with HbA1c measurement at diagnosis, (n, (%)) 5,044 (55.1) 481 (54.7) 2,274 (56.1) 1,365 (54.1) 924 (54.3)
Patients with selected pre-existing conditions
Cardiovascular conditions (%) 19.2 2.5 13.4 25.4 32.4
Microvascular conditions (%) 1.7 0.5 1.0 1.8 3.8
Cancer (%) 4.2 1.3 2.1 5.6 8.4
Oedema (%) 2.5 0.6 2.3 2.7 3.6
Liver Disease (%) 0.6 1.0 0.6 0.5 0.2
Alzheimer/dementia (%) 0.3 0.0 0.1 0.3 1.0
Patients with selected medication use
Antihypertensive agents (%) 59.1 21.4 52.6 69.3 78.4
Lipid-modifying agents (%) 27.8 34.3 24.2 36.4 34.3
Weight-reducing agents (%) 1.2 3.2 1.7 0.5 0.1
Gastroprotective agents (%) 23.3 15.2 20.0 27.2 29.5
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and later physician registration year. The missing indica-
tor for HbA1c values was associated with shorter time to
initiation (Table 2). During the follow-up period, devel-
opment of cardiovascular conditions (Table 2), hospitali-
zation, and new use of antihypertensive, lipid-modifying,
gastroprotective, or weight-reducing agents were asso-
ciated with shorter times to treatment initiation (Table
2).
Figure 2 illustrates that higher HbA1c values at the
end of follow up were associated with lower levels of
non-treatment with antihyperglycaemic medications.
Within each HbA1c category there was a significant
trend for patients in the older age groups to remain
untreated (Figure 2). Among those untreated, the pro-
portion of patients with an HbA1c ≥ 7.5% was not statis-
tically different across age groups (p > 0.05).
Discussion
The present study assessed the time to antihyperglycae-
mic medication initiation in a UK cohort of patients
with newly diagnosed type 2 diabetes and found that the
proportion of patients who had antihyperglycaemic ther-
apy initiated after 2 years of follow up was 51%, with
lower rates of treatment initiation observed in older
compared to younger individuals. This percentage is less
than the 75% of Dutch patients with type 2 diabetes
who initiated oral antihyperglycaemic therapy within 2
years of diagnosis [6]. In a Danish cohort, 70% of newly
diagnosed diabetic patients received antihyperglycaemic
therapy after nearly 6 years of follow up, despite a mean
baseline HbA1c level of 10.2% [5]. Glycaemic control has
been shown to deteriorate over time in patients with
newly diagnosed type 2 diabetes, specifically those
untreated with antihyperglycaemic medication (i.e.,
receiving only diet and lifestyle intervention) [12,16].
Therefore, given that the mean HbA1c was ~8.0%
around the time of diagnosis for those with measure-
ments and in the absence of other factors, more patients
should have been initiated on antihyperglycaemic medi-
cations over the 2-year period than the 51% observed in
the present study.
Although various algorithms for treatment of type 2
diabetes were in place or introduced during the time
period assessed for our study (2003 - 2007), the recom-
mendations are generally similar for patients with newly
diagnosed type 2 diabetes [15,17]. The recommendations
include language stating that lifestyle modifications
should be initiated with follow-up assessment of glycae-
mic control (i.e., fasting glucose and HbA1c)w i t h i na3
to 6 month period. If HbA1c targets are not achieved
with lifestyle modifications, initiation of antihyperglycae-
mic medication should be considered along with conti-
nuation of lifestyle changes. Despite such
recommendations, this study demonstrated that 2 years
after initial diagnosis of type 2 diabetes, a large propor-
tion of patients remain untreated. The proportion of
untreated patients was inversely related to the HbA1c
Figure 1 Kaplan-Meier curves for time to initiation of antihyperglycaemic therapy after diagnosis of type 2 diabetes by age group.
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treatment as HbA1c increased. However, 30% of patients
with an HbA1c value ≥ 7.5% at the end of follow up had
not yet received treatment, despite the apparent need
for treatment based on guidelines.
Management of type 2 diabetes is related to a myriad
of patient-, physician, and systematic-related factors
[18]. Patient age may affect treatment initiation or inten-
sification and limit treatment choices because of the
increased likelihood of co-morbidities and frailty in
older patients [19]. In the present study older patients
were more likely to have pre-existing, co-morbid condi-
tions. After adjusting for these differences, increasing
age was still associated with a decreased likelihood of
physician prescribing of antihyperglycaemic medication.
Similar findings were found with a US cohort of patient
with newly diagnosed type 2 diabetes [20]. Conversely,
higher HbA1c values near the time of diagnosis
increased the likelihood of a physician initiating antihy-
perglycaemic medication. Younger patients had higher
HbA1c at diagnosis, which account for part of the higher
rates of treatment initiation relative to older patients.
When controlling for HbA1c values at diagnosis, older
patients were less likely to initiate treatment than
younger patients. However, a significant interaction was
observed between age and HbA1c values ≥ 7.5% at diag-
nosis, suggesting that the influence of age on non-treat-
ment with antihyperglycaemic medication was reduced
as HbA1c increased above 7.5%. Similar trends were
observed when HbA1c at the end of follow up was used
in the analysis. It is apparent that older patients in this
study were not treated as frequently with antihypergly-
caemic therapy as younger patients with the same
HbA1c level. A recent survey study evaluated the reasons
UK general practitioners do not treat their newly diag-
nosed type 2 diabetes patients with antihyperglycaemic
medications. Reasons cited by the general practitioners
were those related to adequate glycaemic control for
both younger and older patients. However, issues related
to safety of antihyperglycaemic agents, burden to the
patients, or cognitive or physical function of the patient
were selected more often by GPs for not treating their
older patients [21]. Collectively, the present findings are
consistent with the less stringent, glycaemic target
recommendations for older adults, especially those with
pre-existing, co-morbid conditions [22].
In addition, the development or treatment of co-mor-
bid conditions during the follow-up period was posi-
tively associated with initiating antihyperglycaemic
treatment. The new conditions may have prompted the
physician to evaluate glycaemic control in the context of
increased risk factors for cardiovascular disease, as
recommended by treatment guidelines [1,15]. Of the
patients who initiated treatment, median time to start
treatment was approximately 2 months. This is consis-
tent with clinical guidelines in place at the time (2003 -
2007) that suggested initiating antihyperglycaemic treat-
ment if inadequate glycaemic control was present after a
short period (3 to 6 months) of lifestyle intervention
[15,17].
These limitations should be considered when inter-
preting the present results. HbA1c measures around the
time of diagnosis were available for only 55% of the
patients. Thus, the HbA1c results may not reflect the
true baseline value at the time of diagnosis for the entire
cohort. The study had only a 2-year follow-up period. If
one more year of follow up was added, the patient
count would have been reduced by 15-30%. Although
eligible patients had to be at least 30 years old and were
identified using ICD-10 codes for type 2 diabetes, some
Table 2 Adjusted hazard ratios for initiation of
antihyperglycaemic treatment
Variable Patient Sample
(N = 9,158)
Hazard Ratio (95%
CI)
P-value
Baseline
a
Age at first diagnosis, years 0.98 (0.97, 0.99) <
0.0001
HbA1c ≥ 7.5% 2.44 (1.61, 3.70) <
0.0001
Dummy HbA1c (missing = 1) 1.62 (1.06, 2.47) 0.0247
Interaction: Age with HbA1c ≥
7.5%
1.015 (1.008, 1.022) <
0.0001
Gender (male = 1; female = 0) 0.91 (0.86, 0.97) 0.0018
Physician registration years 1.007 (1.003, 1.011) 0.0005
Lipid-modifying agents 1.22 (1.12, 1.32) <
0.0001
Weight-reducing agents 1.59 (1.27, 1.99) <
0.0001
New at follow up
Cardiovascular conditions 1.36 (1.16, 1.59) 0.0001
Antihypertensive agents 1.43 (1.28, 1.61) <
0.0001
Lipid-modifying agents 2.41 (2.21, 2.62) <
0.0001
Gastroprotective agents 1.59 (1.36, 1.88) <
0.0001
Weight-reducing agents 1.38 (1.06, 1.81) 0.0175
Hospitalization 1.37 (1.22, 1.54) <
0.0001
aBaseline variables assessed in 12-month period prior to diagnosis of type 2
diabetes. Non-significant predictors included in the model were indicators for
baseline cardiovascular conditions, microvascular conditions, cerebrovascular
conditions, cancer, liver disease, Alzheimer’s disease/dementia, peptic ulcer
disease, rheumatic conditions, chronic pulmonary disease, hemi- or paraplegia,
oedema, antihypertensive medication use, and gastroprotective medication
use, and indicators for follow-up microvascular conditions, cancer, oedema,
liver disease and Alzheimer’s disease/dementia.
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indentified as having type 2 diabetes, although the num-
ber is likely to have been small.
In summary, in this UK cohort of patients with newly
diagnosed type 2 diabetes, only 51% had antihypergly-
caemic medication initiated over a 2-year period follow-
ing diagnosis, with older patients significantly less likely
to have been prescribed medication by their physicians.
Elevated HbA1c was the strongest factor associated with
initiating antihyperglycaemic medication in these
patients. These results highlight the under-treatment of
older adults with type 2 diabetes. Further research is
needed to better understand the reasons for the
observed differences between younger and older patients
with type 2 diabetes.
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